You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City

    SBC: HBI SOLUTIONS INC.            Topic: 100

    ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical Decision Support System to Optimize Neonatal Nutrition and Growth

    SBC: Medical Predictive Science Corporation            Topic: NICHD

    Project Summary/Abstract: Clinical Decision Support System to Optimize Neonatal Nutrition and Growth Nutrition, defined as energy, macronutrients (protein, fat, and carbohydrates), and micronutrients (e.g., electrolytes), is a critical feature of care for preterm infants in the neonatal intensive unit (NICU). Inadequate nutrition is associated with growth and neurodevelopmental impairment, and inc ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: NCATS

    ABSTRACT Remote trials are led and coordinated by a local investigative team, but are based remotely, typically in the participant’s home. Remote trials offer several advantages over traditional in-person trials including: 1) a wider participant pool, 2) reduced regulatory hurdles, and 3) reduced participant burden. Remote trials face one key methodological limitation: the need for biomarker col ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin

    SBC: NEUIMMUNE BIOLOGICS, INC.            Topic: NHLBI

    ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression

    SBC: Olfa Thera, Inc.            Topic: NIDA

    Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder

    SBC: ELEVEN THERAPEUTICS CORP            Topic: NIDA

    Abstract There is a significant need for new treatments for opioid use disorder (OUD) to manage patients abusing heroin, fentanyl, oxycodone and related drugs. Buprenorphine and methadone are both effective medications for OUD but are agonists with potential for abuse and diversion, and with methadone the risk of respiratory depression and overdose death. Moreover, these compounds are not effectiv ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain

    SBC: Brixton Biosciences, Inc.            Topic: NIAMS

    Project SummaryTotal knee arthroplasty (TKA) is one of the most commonly performed orthopedic surgeries to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. In the United States, over 700,000 TKA procedures are performed each year. Most patients experience significant pain after TKA. To manage this pain, patients are commonly prescribed opioids, contributing to a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Protease Stable N-Terminally Modified Therapeutic Peptides

    SBC: VELUM INC            Topic: NIDDK

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity, and engender fewer side effects than traditional small molecules. This has fueled interest in peptides filling the gap between ‘biologics’ and small molecules, as peptide-based compounds have key desired properties that are distinct both of the other classes. A major challenge remains to extend the short half-life of na ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization

    SBC: FELIX BIOTECHNOLOGY INC            Topic: NIAID

    ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Highly-sensitive, rapid and low cost plasmonic assay platform for Lyme disease diagnosis

    SBC: CIENCIA INC            Topic: NIAID

    Project Summary/Abstract Lyme disease (LD) is the most common vector-borne illness in the United States and represents a considerable diagnostic challenge. 1-3 The current benchmark for LD diagnosis is the standard two-tiered test (STTT), although the modified two-tier test (MTTT) is rapidly becoming an acceptable alternative. 6 These assays are highly specific but have poor sensitivity, especiall ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government